Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders

 Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares
                           By Selling Shareholders

  PR Newswire

  DUBLIN, March 5, 2013

DUBLIN, March 5, 2013 /PRNewswire/ --Jazz Pharmaceuticals plc (Nasdaq: JAZZ)
today announced the pricing of a previously announced underwritten public
offering of 5,375,000 of its ordinary shares held by certain of its existing
shareholders, offered at a price to the public of $58.50 per share. Jazz
Pharmaceuticals will not receive any proceeds from the sale of ordinary shares
by the selling shareholders in the offering, and its total number of ordinary
shares outstanding will not change as a result of the offering. The offering
is expected to close on or about March 8, 2013, subject to customary closing
conditions.

Barclays Capital Inc. is acting as sole book-running manager and underwriter
in this offering.

A registration statement relating to the shares described above was previously
filed with and has become effective by rule of the Securities and Exchange
Commission ("SEC"). A final prospectus supplement relating to the offering
will be filed with the SEC. Copies of the final prospectus supplement and
related prospectus, when available, may be obtained from Barclays Capital
Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, or by telephone at 1-888-603-5847, or by email at
Barclaysprospectus@broadridge.com . This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any
sale of, the shares in any state or other jurisdiction which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on
improving patients' lives by identifying, developing and commercializing
innovative products that address unmet medical needs. The company has a
diverse portfolio of products in the areas of narcolepsy, oncology, pain and
psychiatry. The company's U.S. marketed products in these areas include:
Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia
chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine,
USP) HD, FazaClo LD, and Luvox CR® (fluvoxamine maleate). Outside of the U.S.,
Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma
division.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995

This press release contains forward-looking statements, including, but not
limited to, statements related to the public offering of ordinary shares of
Jazz Pharmaceuticals. These forward-looking statements are based on Jazz
Pharmaceuticals' current expectations and inherently involve significant risks
and uncertainties. Jazz Pharmaceuticals' actual results and the timing of
events could differ materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which include,
without limitation, risks and uncertainties associated with market conditions
and the satisfaction of customary closing conditions related to the public
offering. Additional risks and uncertainties relating to the public offering,
Jazz Pharmaceuticals and its business can be found under the caption "Risk
Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange
Commission filings and reports (Commission File No. 001-33500), including in
its Annual Report on Form 10-K for the year ended December 31, 2012. Jazz
Pharmaceuticals undertakes no duty or obligation to update any forward-looking
statements contained in this release as a result of new information, future
events or changes in its expectations.

Contact: For Investors: Kathee Littrell, Vice President, Investor Relations,
Jazz Pharmaceuticals plc, Ireland, +353-1-634-7887, U.S., +1-650-496-2717; For
Media: Ami Knoefler, Executive Director, Investor Relations and Corporate
Communications, Jazz Pharmaceuticals plc, Ireland, +353-1-638-1032, U.S.,
+1-650-496-2947